This is one of the better examples of where the use of 'open source' rather than 'free' distracts everyone from the end goal.
This particular case may well be a beat-up, but there's undeniably a regular habit within pharma to not publish neutral or negative results, and we don't know how useful those data may be simply because we don't have access to them.
AFAIK no country has laws requiring this, so it's not a regulatory / enforcement problem - it's a legislative one.
This particular case may well be a beat-up, but there's undeniably a regular habit within pharma to not publish neutral or negative results, and we don't know how useful those data may be simply because we don't have access to them.
AFAIK no country has laws requiring this, so it's not a regulatory / enforcement problem - it's a legislative one.